Artios Pharma

Executive Summary

Artios Pharma, a private UK-based biotechnology company founded in 2016, is a leader in targeting DNA Damage Response (DDR) pathways for cancer therapy. Building on foundational insights from PARP inhibitors, the company develops first- and best-in-class small molecules for difficult-to-treat solid tumors. Its pipeline includes clinical-stage inhibitors of ATR (ART0380) and Polθ (ART4215), alongside a proprietary discovery platform. Artios has raised significant venture capital and maintains a strong scientific advisory board, positioning it as a key player in the DDR space. The company's strategy focuses on addressing resistance mechanisms and expanding the therapeutic index of established modalities, with potential for both monotherapy and combination approaches. Artios' most advanced programs are in Phase 1/2, with near-term catalysts expected in 2026. The Polθ inhibitor ART4215 targets homologous recombination-deficient tumors, while the ATR inhibitor ART0380 is being evaluated in multiple solid tumor types. Upcoming milestones include early efficacy data from ongoing trials and potential expansion into new indications. The company also leverages its discovery platform to generate novel DDR targets. With a robust cash runway and strong preclinical validation, Artios is well-positioned to deliver proof-of-concept data that could drive significant value inflection.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 initiation of ART4215 (Polθ inhibitor) in HR-deficient tumors70% success
• Q4 2026Phase 1/2 efficacy data update for ART0380 (ATR inhibitor)60% success
• TBDPotential partnership or licensing deal for non-core DDR assets40% success